Fluticasone Propionate Powder, Metered
Product Images NDC 50090-7076

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate (NDC 50090-7076). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fluticasone Propionate Diskus Spl Graphic 01)

Chemical structure of fluticasone propionate, the active ingredient in FLUTICASONE PROPIONATE DISKUS. The diagram shows the molecular structure with labeled atoms and bonds, including fluorine, oxygen, carbon, hydrogen, sulfur, and a propionate group.*

FDA Label Image

Figure 1 (Fluticasone Propionate Diskus Spl Graphic 02)

A line graph comparing the percentage change from baseline in FEV1 over 12 weeks between Fluticasone Propionate DISKUS 100 mcg twice daily and placebo. The x-axis shows the weeks from 0 to 12, and the y-axis shows the % change from baseline in FEV1. Fluticasone shows a higher increase than placebo throughout the study period.*

FDA Label Image

Figure 2 (Fluticasone Propionate Diskus Spl Graphic 03)

A line graph showing the percentage change from baseline in FEV1 over 12 weeks for Fluticasone Propionate DISKUS 100 mcg twice daily compared to placebo. The x-axis represents weeks (0 to 12 and Endpoint), and the y-axis represents the percent change from baseline in FEV1, with baseline values noted for each group. Data points for Fluticasone Propionate show an overall increase, while placebo shows minimal change.*

FDA Label Image

Figure 3 (Fluticasone Propionate Diskus Spl Graphic 04)

A line graph comparing the percentage change from baseline in FEV1 over 12 weeks plus an endpoint measurement for Fluticasone Propionate DISKUS 250 mcg twice daily versus placebo. The x-axis shows weeks 0 to 12 and endpoint, while the y-axis displays percent change from baseline in FEV1. The Fluticasone group shows a rapid increase and stable improvement, whereas the placebo group remains near baseline with minor fluctuations.*

FDA Label Image

Figure 4 (Fluticasone Propionate Diskus Spl Graphic 05)

A line graph showing the percent change from baseline in FEV1 over 12 weeks comparing Fluticasone Propionate DISKUS 500 mcg twice daily to placebo. The graph plots weeks on the x-axis and percent change in FEV1 on the y-axis, illustrating higher improvement with Fluticasone Propionate DISKUS over placebo throughout the study period.*

FDA Label Image

Figure A (Fluticasone Propionate Diskus Spl Graphic 06)

Illustration showing the components of a Fluticasone Propionate Diskus 100 mcg inhalation powder device. Labeled parts include the outer case, mouthpiece, lever, thumb grip, and dose counter. The label on the device indicates 60 blisters and dosage strength of 100 mcg powder per inhalation.*

FDA Label Image

Figure B (Fluticasone Propionate Diskus Spl Graphic 07)

An instructional illustration showing a person holding a Fluticasone Propionate Diskus inhaler. The image demonstrates a step where the user pushes the inhaler outward, indicated by a right-pointing arrow, likely to prepare the device for inhalation.*

FDA Label Image

Figure C (Fluticasone Propionate Diskus Spl Graphic 08)

An instructional illustration depicting hands holding a FLUTICASONE PROPIONATE DISKUS inhaler device. An arrow indicates the direction to open or operate the device, demonstrating how to use the metered powder for respiratory inhalation.*

FDA Label Image

Figure D (Fluticasone Propionate Diskus Spl Graphic 09)

Illustration of a woman demonstrating the use of a dry powder inhaler device, holding it near her mouth as she appears to inhale the medication. The device is small, red, and circular, typical for respiratory inhalation products like fluticasone propionate DISKUS.*

FDA Label Image

Figure E (Fluticasone Propionate Diskus Spl Graphic 10)

Illustration showing a woman using a fluticasone propionate inhaler, demonstrating the respiratory (inhalation) administration method for this metered powder dosage form.*

FDA Label Image

Figure F (Fluticasone Propionate Diskus Spl Graphic 11)

An illustration showing hands demonstrating how to slide the lever on a fluticasone propionate Diskus inhaler, pushing the lever to the left as indicated by an arrow, to prepare the device for inhalation.*

FDA Label Image

Figure G (Fluticasone Propionate Diskus Spl Graphic 12)

An illustration showing a person rinsing their mouth with water over a sink, likely demonstrating a post-inhalation mouth rinse step associated with respiratory powder medications.*

FDA Label Image

Figure H (Fluticasone Propionate Diskus Spl Graphic 13)

FLUTICASONE PROPIONATE DISKUS inhaler device for respiratory administration. The orange, disk-shaped inhaler contains 60 blisters of fluticasone propionate inhalation powder, each with a dosage of 100 mcg. The label includes a space to record the date the device is opened and its use-by date.*

FDA Label Image

Label Image (Lbl500907076)

FLUTICASONE PROPIONATE DISKUS 50 ug/1 metered powder inhalation packaging label from A-S Medication Solutions. The label includes product NDC 50090-7076-0, storage instructions to keep between 68 to 77 degrees Fahrenheit in a dry place away from direct heat or sunlight, and directions to use one diskus inhalation device containing 1 foil strip of blisters.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.